Ex-CEO at China Biologic spearheads $3.9B buyout offer; Syneos acquires Kinapse, adding 600 staffers
→ Just weeks after Beijing-based China Biologic $CBPO booted its chairman and CEO David Gao “for cause,” the executive has bounced back at the head of a prominent consortium looking to buy the company in a $3.9 billion all-cash bid.
Gao’s group — which includes GL Capital Group, Bank of China Group Investment Limited and CDH Investments — is bidding $118 a share for the company. That is well ahead of the $3.65 billion offer on the table from CITIC Capital.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.